Namuscla Europeiska unionen - norska - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic lidelser - hjertetapi - namuscla er indikert for symptomatisk behandling av myotonia hos voksne pasienter med ikke-dystrophic myotonic lidelser.

Hydromorfonhydroklorid Kalceks 2 mg/ ml Norge - norska - Statens legemiddelverk

hydromorfonhydroklorid kalceks 2 mg/ ml

as kalceks - hydromorfonhydroklorid - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml

Paritdam 300 mg Norge - norska - Statens legemiddelverk

paritdam 300 mg

accord healthcare b.v. - bupropionhydroklorid - tablett med modifisert frisetting - 300 mg

Sitagliptin Accord Europeiska unionen - norska - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Paritdam 150 mg Norge - norska - Statens legemiddelverk

paritdam 150 mg

accord healthcare b.v. - bupropionhydroklorid - tablett med modifisert frisetting - 150 mg

Efexor Depot 150 mg Norge - norska - Statens legemiddelverk

efexor depot 150 mg

upjohn eesv - venlafaksinhydroklorid - depotkapsel, hard - 150 mg

Efexor Depot 75 mg Norge - norska - Statens legemiddelverk

efexor depot 75 mg

upjohn eesv - venlafaksinhydroklorid - depotkapsel, hard - 75 mg

Enalapril/Lercanidipine Krka 20 mg / 10 mg Norge - norska - Statens legemiddelverk

enalapril/lercanidipine krka 20 mg / 10 mg

krka sverige ab - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg / 10 mg

Enalapril/Lercanidipine Krka 10 mg / 10 mg Norge - norska - Statens legemiddelverk

enalapril/lercanidipine krka 10 mg / 10 mg

krka sverige ab - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg / 10 mg

Morfin 10 mg/ ml Norge - norska - Statens legemiddelverk

morfin 10 mg/ ml

orifarm healthcare a/s - morfinhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml